Cardurion Pharmaceuticals Announces Initiation of Phase 1 Study of CRD-733
Cardurion Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) for CRD-733, a Phosphodiesterase-9…
Read More...
Read More...
